Published in Acta Neuropathol on February 08, 2011
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. Nature (2012) 1.77
Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains. Alzheimers Res Ther (2012) 1.22
Involvement of perineuronal and perisynaptic extracellular matrix in Alzheimer's disease neuropathology. Brain Pathol (2012) 0.99
The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions. EMBO Mol Med (2011) 0.96
Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am J Pathol (2013) 0.93
Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core. Neurosci Lett (2011) 0.89
Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer's disease and in AβPP transgenic mice using a novel monoclonal antibody. J Alzheimers Dis (2012) 0.84
Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy. Curr Neuropharmacol (2013) 0.83
Oxidative Stress during the Progression of β-Amyloid Pathology in the Neocortex of the Tg2576 Mouse Model of Alzheimer's Disease. Oxid Med Cell Longev (2015) 0.81
An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice. Neurobiol Aging (2015) 0.81
Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease. Acta Neuropathol (2015) 0.76
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology (1991) 23.01
Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology (2002) 7.73
Are the dorsal and ventral hippocampus functionally distinct structures? Neuron (2010) 6.74
Immortalization of hypothalamic GnRH neurons by genetically targeted tumorigenesis. Neuron (1990) 4.15
The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank (2008) 4.13
Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol (2002) 3.62
The hippocampus and memory: insights from spatial processing. Nat Rev Neurosci (2008) 3.49
Classification and basic pathology of Alzheimer disease. Acta Neuropathol (2009) 3.24
Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2005) 2.97
Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron (1995) 2.90
Take five--BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J (2004) 2.72
Alzheimer's disease affects limbic nuclei of the thalamus. Acta Neuropathol (1991) 2.41
Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci (2002) 2.35
Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci (2003) 2.24
Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron (2010) 2.10
The perforant path: projections from the entorhinal cortex to the dentate gyrus. Prog Brain Res (2007) 2.02
Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med (2008) 2.01
Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J Neurosci (1998) 2.00
Presenilin-1 mutations in Alzheimer's disease. Nature (2000) 1.97
The entorhinal cortex of the mouse: organization of the projection to the hippocampal formation. Hippocampus (2003) 1.80
Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett (1996) 1.78
On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry (2006) 1.72
The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. Neuroscience (2001) 1.51
Laminating the hippocampus. Nat Rev Neurosci (2006) 1.50
beta-amyloid is different in normal aging and in Alzheimer disease. J Biol Chem (2005) 1.48
Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. Biochemistry (2005) 1.47
Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival. J Neurochem (2002) 1.46
Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol (2010) 1.46
Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol (2009) 1.44
Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Abeta amyloidosis. J Neurosci (2002) 1.41
Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutamyl peptides. Proc Natl Acad Sci U S A (1987) 1.37
The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry (1999) 1.37
The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42. J Biol Chem (2009) 1.32
Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett (2004) 1.30
Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry (2009) 1.25
Noradrenergic innervation of the adult rat hippocampal formation. J Comp Neurol (1980) 1.24
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm (Vienna) (2009) 1.22
An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes. J Biol Chem (1987) 1.21
Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry (2008) 1.18
Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol (2008) 1.16
Alzheimer's disease as proteolytic disorders: anabolism and catabolism of beta-amyloid. Neurobiol Aging (1998) 1.05
Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. Biochim Biophys Acta (2006) 1.04
Cognitive impact of neuronal pathology in the entorhinal cortex and CA1 field in Alzheimer's disease. Neurobiol Aging (2005) 1.02
N-terminal truncated pyroglutamyl beta amyloid peptide Abetapy3-42 shows a faster aggregation kinetics than the full-length Abeta1-42. Biopolymers (2009) 1.01
Primary structure and functional expression of a glutaminyl cyclase. Proc Natl Acad Sci U S A (1991) 0.96
Seeding neuritic plaques from the distance: a possible role for brainstem neurons in the development of Alzheimer's disease pathology. Neurodegener Dis (2008) 0.96
Beta-amyloid plaques: stages in life history or independent origin? Dement Geriatr Cogn Disord (1998) 0.95
Neuronal loss and neurofibrillary degeneration in the hippocampal cortex in late-onset sporadic Alzheimer's disease. Psychiatry Clin Neurosci (2000) 0.94
Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ. J Neurochem (2008) 0.93
Glutaminyl-cyclase expression in the bovine/porcine hypothalamus and pituitary. J Neuroendocrinol (1995) 0.92
The laminar distribution of neuritic plaques in the fascia dentata of patients with Alzheimer's disease. Acta Neuropathol (1988) 0.91
Diffuse amyloid deposition, but not plaque number, is reduced in amyloid precursor protein/presenilin 1 double-transgenic mice by pathway lesions. Neuroscience (2003) 0.89
Selective deposition of amyloid-beta protein in the entorhinal-dentate projection of a transgenic mouse model of Alzheimer's disease. J Neurosci Res (1998) 0.89
Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbits. J Neuroimmunol (2009) 0.89
Developmental expression and subcellular localization of glutaminyl cyclase in mouse brain. Int J Dev Neurosci (2009) 0.88
Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease. Acta Neuropathol (2010) 0.83
Noradrenaline nerve terminals in the hippocampal region of the rat and the guinea pig. Z Zellforsch Mikrosk Anat (1967) 0.80
Basal forebrain cholinergic immunolesion by 192IgG-saporin: evidence for a presynaptic location of subpopulations of alpha 2- and beta-adrenergic as well as 5-HT2A receptors on cortical cholinergic terminals. Neurochem Res (1997) 0.76
Cohesin mediates transcriptional insulation by CCCTC-binding factor. Nature (2008) 12.01
Cell death in Pseudomonas aeruginosa biofilm development. J Bacteriol (2003) 3.74
Dissociation of cohesin from chromosome arms and loss of arm cohesion during early mitosis depends on phosphorylation of SA2. PLoS Biol (2005) 3.72
Distinct functions of condensin I and II in mitotic chromosome assembly. J Cell Sci (2004) 3.14
Condensin I stabilizes chromosomes mechanically through a dynamic interaction in live cells. Curr Biol (2006) 2.69
Live-cell imaging reveals a stable cohesin-chromatin interaction after but not before DNA replication. Curr Biol (2006) 2.47
ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J (2010) 2.35
Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun (2002) 2.28
Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proc Natl Acad Sci U S A (2007) 2.13
Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med (2008) 2.01
Tissue transglutaminase is not a biochemical marker for Alzheimer's disease. Neurobiol Aging (2013) 2.00
Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A (2006) 1.81
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. Nature (2012) 1.77
On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry (2006) 1.72
Identity and effects of quorum-sensing inhibitors produced by Penicillium species. Microbiology (2005) 1.67
The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci U S A (2003) 1.62
Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J (2012) 1.61
Aneuploidy and DNA replication in the normal human brain and Alzheimer's disease. J Neurosci (2007) 1.52
Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol (2009) 1.44
Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol (2011) 1.41
Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes (2003) 1.37
Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept (2005) 1.32
Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J Neurosci Res (2007) 1.30
Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett (2004) 1.30
Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry (2009) 1.25
P2X7 receptor expression after ischemia in the cerebral cortex of rats. J Neuropathol Exp Neurol (2004) 1.21
Glutaminyl cyclases from animals and plants: a case of functionally convergent protein evolution. Biol Chem (2008) 1.20
Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent. Glia (2003) 1.19
NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42. J Biol Chem (2008) 1.19
Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry (2008) 1.18
Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem Biophys Res Commun (2007) 1.17
Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. J Biol Chem (2010) 1.16
Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology (2003) 1.13
Samp1 is a component of TAN lines and is required for nuclear movement. J Cell Sci (2012) 1.11
Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells. Am J Physiol Cell Physiol (2004) 1.08
The transcription factor Yin Yang 1 is an activator of BACE1 expression. J Neurochem (2006) 1.08
Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation. J Neurosci (2011) 1.08
Aging-related down-regulation of neprilysin, a putative beta-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of beta-amyloid plaques. Neurosci Lett (2003) 1.08
Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. J Alzheimers Dis (2010) 1.07
Infection control in the management of highly pathogenic infectious diseases: consensus of the European Network of Infectious Disease. Lancet Infect Dis (2009) 1.06
Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J Magn Reson Imaging (2006) 1.05
AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J Alzheimers Dis (2002) 1.05
Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets. PLoS Pathog (2013) 1.04
Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. Biochim Biophys Acta (2006) 1.04
Reduced infarct volume and differential effects on glial cell activation after hyperbaric oxygen treatment in rat permanent focal cerebral ischaemia. Eur J Neurosci (2005) 1.03
Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats. J Histochem Cytochem (2007) 1.01
Neuroprotection against iron-induced cell death by perineuronal nets - an in vivo analysis of oxidative stress. Am J Neurodegener Dis (2012) 1.01
N-Terminal pyroglutamate formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation. J Neurochem (2012) 1.01
Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition. Eur J Biochem (2002) 1.00
Involvement of perineuronal and perisynaptic extracellular matrix in Alzheimer's disease neuropathology. Brain Pathol (2012) 0.99
Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. J Biol Chem (2012) 0.99
Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. Int J Dev Neurosci (2004) 0.99
Increase of locomotor activity underlying the behavioral disinhibition in tg2576 mice. Behav Neurosci (2007) 0.99
Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model. Int J Alzheimers Dis (2010) 0.98
Decomposition and long-lasting downregulation of extracellular matrix in perineuronal nets induced by focal cerebral ischemia in rats. J Neurosci Res (2005) 0.97
The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions. EMBO Mol Med (2011) 0.96
Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease. Biol Chem (2008) 0.96
NLS-mediated NPC functions of the nucleoporin Pom121. FEBS Lett (2010) 0.95
Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study. Neurodegener Dis (2012) 0.95
Isolation of an isoenzyme of human glutaminyl cyclase: retention in the Golgi complex suggests involvement in the protein maturation machinery. J Mol Biol (2008) 0.95
Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme. J Neurochem (2005) 0.95
Bepridil and amiodarone simultaneously target the Alzheimer's disease beta- and gamma-secretase via distinct mechanisms. J Neurosci (2010) 0.94
Surface motility in Pseudomonas sp. DSS73 is required for efficient biological containment of the root-pathogenic microfungi Rhizoctonia solani and Pythium ultimum. Microbiology (2003) 0.94
Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. J Neurochem (2005) 0.94
Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. Int J Biochem Cell Biol (2006) 0.94
The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship. J Med Chem (2006) 0.93